Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2016 - GlobalData

Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2016

Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2016 - GlobalData
Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2016
Published Aug 31, 2016
393 pages — Published Aug 31, 2016
Price US$ 2,500.00  |  Buy this Report Now

About This Report

  
Abstract:

Summary

GlobalData's clinical trial report, Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2016' provides an overview of Systemic Lupus Erythematosus clinical trials scenario. This report provides top line data relating to the clinical trials on Systemic Lupus Erythematosus. Report includes an overview of trial numbers and their average enrollment in top countries conducted across the globe. The report offers coverage of disease clinical trials by region, country (G7 & E7), phase, trial status, end points status and sponsor type. Report also provides prominent drugs for in-progress trials (based on number of ongoing trials). GlobalData Clinical Trial Reports are generated using GlobalDatas proprietary database - Pharma eTrack Clinical trials database. Clinical trials are collated from 80+ different clinical trial registries, conferences, journals, news etc across the globe. Clinical trials database undergoes periodic update by dynamic process.

The report enhances the decision making capabilities and helps to create an effective counter strategies to gain competitive advantage.

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global clinical trials landscape
- Report provides top level data related to the clinical trials by Region, Country (G7 & E7), Trial Status, Trial Phase, Sponsor Type and End point status
- The report reviews top companies involved and enlists all trials (Trial title, Phase, and Status) pertaining to the company
- The report provides all the unaccomplished trials (Terminated, Suspended and Withdrawn) with reason for unaccomplishment
- The Report provides enrollment trends for the past five years
- Report provides latest news for the past three months

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Reasons to buy

- Assists in formulating key business strategies with regards to investment
- Helps in identifying prominent locations for conducting clinical trials which saves time and cost
- Provides top level analysis of Global Clinical Trials Market which helps in identifying key business opportunities
- Supports understanding of trials count and enrollment trends by country in global therapeutics market
- Aids in interpreting the success rates of clinical trials by providing a comparative scenario of completed and uncompleted (terminated, suspended or withdrawn) trials
- Facilitates clinical trial assessment of the indication on a global, regional and country level

*Note: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

  
Source:
Document ID
GDHC3699CTIDB
Industry
Format:
PDF Adobe Acrobat
Buy Now

Sections

TitleStarting PageNumber of Pages
Table of Contents23
  List of Tables31
  List of Figures41
Report Guidance51
Clinical Trials by Region69
  Clinical Trials and Average Enrollment by Country73
    Top Five Countries Contributing to Clinical Trials in Asia-Pacific101
    Top Five Countries Contributing to Clinical Trials in Europe111
    Top Countries Contributing to Clinical Trials in North America121
    Top Five Countries Contributing to Clinical Trials in Middle East and Africa131
    Top Five Countries Contributing to Clinical Trials in Central and South America141
Clinical Trials by G7 Countries: Proportion of Systemic Lupus Erythematosus to Immunology Clinical Trials151
Clinical Trials by Phase in G7 Countries161
Clinical Trials in G7 Countries by Trial Status171
Clinical Trials by E7 Countries: Proportion of Systemic Lupus Erythematosus to Immunology Clinical Trials181
Clinical Trials by Phase in E7 Countries191
Clinical Trials in E7 Countries by Trial Status201
Clinical Trials by Phase212
  In Progress Trials by Phase221
Clinical Trials by Trial Status231
Clinical Trials by End Point Status241
Subjects Recruited Over a Period of Time251
Clinical Trials by Sponsor Type261
Prominent Sponsors273
  Top Companies Participating in Systemic Lupus Erythematosus Therapeutics Clinical Trials282
Prominent Drugs301
Latest Clinical Trials News on Systemic Lupus Erythematosus316
  Aug 03, 2016: Anthera Pharmaceuticals Announces Completion of Dosing in CHABLIS-SC1 Phase 3 Clinical Study with Blisibimod311
  Jul 19, 2016: Kadmon Data Published in Science Signaling Show ROCK2 Signaling as a Key Modulator of T Follicular Helper Cell Function in Autoimmune Diseases311
  Jun 28, 2016: Anthera Provides Clinical Program Update for Blisibimod321
  Jun 20, 2016: Dalazatide as a Potential Immunotherapy for Lupus to be Presented at Immunology Conference331
  Jun 09, 2016: Mallinckrodt Presents New Data from 44-Week Open Label Extension Of Company-Sponsored H.P. Acthar Gel Trial in Lupus331
  Jun 08, 2016: New Phase III data shows greater treatment response with GSK s Benlysta (belimumab) vs placebo in patients with highly active SLE341
  Jun 08, 2016: UCB presents Phase 1 results for dapirolizumab pegol at the Annual European Congress of Rheumatology (EULAR 2016)351
  Jun 07, 2016: First European Patients Commence Dosing In Lupuzor's Pivotal Phase III Study361
  Jun 02, 2016: AbbVie Highlights on Venetoclax (ABT-199) at the Annual European Congress of Rheumatology (EULAR 2016)361
Clinical Trial Profile Snapshots37353
Appendix3903
  Abbreviations3901
  Definitions3901
  Research Methodology3911
  Secondary Research3911
  About GlobalData3921
  Contact Us3921
  Disclaimer3921
Source3931

Table Of Contents

GlobalData—GlobalData uses proprietary data sources, tools and techniques to gather, analyze and represent the latest and the most reliable information essential for a business to sustain a competitive edge. GlobalData is a comprehensive source of insights and analysis with coverage across the oil & gas, power, alternative energy, nuclear power, petrochemicals, medical equipment and healthcare industries.

About the Author


Cite this Report

  
MLA:
GlobalData. "Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2016" Aug 31, 2016. Alacra Store. Nov 16, 2026. <http://www.alacrastore.com/storecontent/GlobalData/Systemic-Lupus-Erythematosus-Global-Clinical-Trials-Review-H2-2016-2085-23697>
  
APA:
GlobalData. (2016). Systemic Lupus Erythematosus Global Clinical Trials Review, H2, 2016 Aug 31, 2016. New York, NY: Alacra Store. Retrieved Nov 16, 2026 from <http://www.alacrastore.com/storecontent/GlobalData/Systemic-Lupus-Erythematosus-Global-Clinical-Trials-Review-H2-2016-2085-23697>
  
US$ 2,500.00
$  £  €
Have a Question?

Any questions about the report you're considering? Our Customer Service Team can help! Or visit our FAQs.

More Research

Search all our Market Research from one place.